Mokam Life Science Research Institute Holds 42nd Anniversary Ceremony

"AI Drug Discovery: Not a Matter of Possibility, but of Timing...
We Will Further Enhance Our Capabilities"

Mokam Life Science Research Institute announced on the 11th that it held its 42nd anniversary celebration at its Seocho-dong research facility in Seoul on May 8.

Mokam Institute of Life Science Holds 42nd Anniversary Ceremony. Mokam Institute of Life Science

Having long established a reputation as a leading center for bio-pharmaceutical development, Mokam Research Institute transformed itself in 2022 into an artificial intelligence (AI)-based drug discovery institute. Since then, the institute has accelerated end-to-end drug development research by expanding into AI-driven translational research areas, including the development of an AI platform for mRNA therapeutics and vaccine development, the creation of an integrated mRNA-LNP system that covers sequence design, lipid nanoparticle (LNP) delivery, and expression optimization, as well as candidate screening based on efficacy and toxicity prediction, and the identification and validation of disease treatment targets and biomarkers.

At the anniversary ceremony, Hyunjin Shin, Director of Mokam Life Science Research Institute, stated, "We are now venturing down the uncharted path of AI drug discovery. If we persevere without wavering or becoming complacent, maintaining the resolve of a mountain, we will ultimately prove that we were right." He added, "AI drug discovery is not a question of possibility but of timing. Only those who are prepared will achieve success, so we will continue to further enhance the institute's capabilities."

During the ceremony, Ilhun Kim, Head of the Planning and Administration Office, was honored for 20 years of long-term service.

Meanwhile, in March, Mokam Research Institute was selected as a partner organization for the "K-Moonshot" project, a nationwide AI research and innovation program led by the Ministry of Science and ICT. The institute is contributing to improving productivity and research efficiency in the drug development process by leveraging its AI-based drug discovery capabilities in the "Advanced Bio & New Drug Development" field.

This content was produced with the assistance of AI translation services.